BRAFV600E efficient transformation and induction of microsatellite instability versus KRASG12V induction of senescence markers in human colon cancer cells

Neoplasia

Volumn 11, Issue 11, 2009, Pages 1116-1131

  Oikonomou, Eftychia ^a   Makrodouli, Eleni ^a   Evagelidou, Maria ^b   Joyce, Tobias ^a   Probert, Lesley ^b   Pintzas, Alexander ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL MARKER; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; CELL STRAIN CACO 2; CELL STRUCTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE;

EID: 70350738477     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09514     Document Type: Article

References (60)

1. Bos JL (1989). Ras oncogenes in human cancer: a review. Cancer Res 49, 4682-4689. (Pubitemid 19213607)
2. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, et al. (2004). Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22, 4584-4594. (Pubitemid 41185126)
3. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, and Soderkvist P (2004). Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25, 527-533. (Pubitemid 38528645)
4. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62, 6997-7000. (Pubitemid 35424092)
5. Malumbres M and Barbacid M (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer 3, 459-465.
6. COSMIC Database. Available at: http://www.sanger.ac.uk/. Accessed May 11, 2009.
7. Al-Mulla F, Milner-White EJ, Going JJ, and Birnie GD (1999). Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187, 433-438. (Pubitemid 29118275)
8. Andreyev HJ, Norman AR, Cunningham D, Oates JR, and Clarke PA (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90, 675-684.
9. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, Knauer M, Drexel H, Wenzl E, De Vries A, and Lang A (2009). Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21, 1283-1287.
10. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, et al. (2003). Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63, 8132-8137. (Pubitemid 37549459)
11. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954. (Pubitemid 34716871)
12. Wellbrock C, Karasarides M, and Marais R (2004). The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5, 875-885. (Pubitemid 39486539)
13. Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, et al. (2004). Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22, 3950-3957. (Pubitemid 41079877)
14. Genot E, Reif K, Beach S, Kramer I, and Cantrell D (1998). p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Oncogene 17, 1731-1738. (Pubitemid 28482650)
15. Cip1. Mol Cell Biol 17, 5598-5611.
16. Kasid U and Dritschilo A (2003). RAF antisense oligonucleotide as a tumor radiosensitizer. Oncogene 22, 5876-5884. (Pubitemid 37176708)
17. Alao JP (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6, 24.
18. Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A, and Gheber L (2005). Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 93, 338-345. (Pubitemid 43080036)
19. Coleman ML, Marshall CJ, and Olson MF (2003). Ras promotes p21(Waf1/ Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 22, 2036-2046.
20. Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, et al. (1998). Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 101, 153-159. (Pubitemid 28058914)
21. Zhu J, Woods D, McMahon M, and Bishop JM (1998). Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 12, 2997-3007. (Pubitemid 28469302)
22. Janderova-Rossmeislova L, Novakova Z, Vlasakova J, Philimonenko V, Hozak P, and Hodny Z (2007). PML protein association with specific nucleolar structures differs in normal, tumor and senescent human cells. J Struct Biol 159, 56-70. (Pubitemid 46880553)
23. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, and Peeper DS (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
24. INK4a. Cell 88, 593-602.
25. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa- Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al. (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40, 600-608. (Pubitemid 351601205)
26. Garnett MJ and Marais R (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
27. Zweibaum A, Triadou N, Kedinger M, Augeron C, Robine-Leon S, Pinto M, Rousset M, and Haffen K (1983). Sucrase-isomaltase: a marker of foetal and malignant epithelial cells of the human colon. Int J Cancer 32, 407-412.
28. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, and BodmerWF(1997). β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94, 10330-10334. (Pubitemid 27407041)
29. De Bosscher K, Hill CS, and Nicolas FJ (2004). Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J 379, 209-216. (Pubitemid 38491376)
30. Djelloul S, Forgue-Lafitte ME, Hermelin B, Mareel M, Bruyneel E, Baldi A, Giordano A, Chastre E, and Gespach C (1997). Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett 406, 234-242.
31. Roberts ML, Drosopoulos KG, Vasileiou I, Stricker M, Taoufik E, Maercker C, Guialis A, Alexis MN, and Pintzas A (2006). Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int J Cancer 118, 616-627. (Pubitemid 43076010)
32. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al. (1998). United Kingdom Co-ordinating Committee on Cancer Research (UKCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77, 1-10. (Pubitemid 28029765)
33. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, and Pereira-Smith O (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92, 9363-9367.
34. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, and Hamelin R (2002). Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123, 1804-1811. (Pubitemid 35408304)
35. Ferbeyre G (2007). Barriers to Ras transformation. Nat Cell Biol 9, 483-485.
36. INK4a expression during cellular senescence. Nature 409, 1067-1070.
37. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, and Baylin SB (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55, 4525-4530.
38. Russo MT, Blasi MF, Chiera F, Fortini P, Degan P, Macpherson P, Furuichi M, Nakabeppu Y, Karran P, Aquilina G, et al. (2004). The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair-deficient cells. Mol Cell Biol 24, 465-474. (Pubitemid 38010070)
39. V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65, 2465-2473.
40. Dhillon AS and Kolch W (2004). Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 5, 303-304. (Pubitemid 38482064)
41. Benjamin CL and Ananthaswamy HN (2008). Oncogenic potential of BRAF versus RAS. Cancer Lett 261, 137-146.
42. Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, and Baffet G (2008). RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 27, 5315-5325.
43. Lefloch R, Pouyssegur J, and Lenormand P (2008). Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol 28, 511-527.
44. Garnett MJ, Rana S, Paterson H, Barford D, and Marais R (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20, 963-969. (Pubitemid 41814884)
45. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, and Marais R (2006). In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66, 9483-9491.
46. Banerji U, Affolter A, Judson I, Marais R, and Workman P (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7, 737-739. (Pubitemid 351551026)
47. Kolch W (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ ERK pathway by protein interactions. Biochem J 351 (Pt 2), 289-305.
48. Razidlo GL, Kortum RL, Haferbier JL, and Lewis RE (2004). Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem 279, 47808-47814. (Pubitemid 39540930)
49. Xing HR, Cordon-Cardo C, Deng X, Tong W, Campodonico L, Fuks Z, and Kolesnick R (2003). Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med 9, 1266-1268. (Pubitemid 37279848)
50. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, and Lowe SW (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12, 3008-3019. (Pubitemid 28469303)
51. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, and Cichowski K (2006). A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459-472. (Pubitemid 44872980)
52. Wang G, Dombkowski A, Chuang L, and Xu XX (2004). The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Res 14, 303-314.
53. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, and Velculescu VE (2002).Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934.
54. Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, and Schwartz S Jr (2005). Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 24, 7630-7634. (Pubitemid 41638038)
55. Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, Arribas J, Baselga J, and Tabernero J (2008). Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99, 1607-1612.
56. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58, 5248-5257. (Pubitemid 28521189)
57. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, et al. (2009). Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27, 1814-1821.
58. Des GG, Uzzan B, Nicolas P, Schischmanoff O, and Morere JF (2009). Microsatellite instability: a predictive marker in metastatic colorectal cancer? Target Oncol 4, 57-62.
59. Dunican DS, McWilliam P, Tighe O, Parle-McDermott A, and Croke DT (2002). Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by highdensity cDNA array hybridization. Oncogene 21, 3253-3257. (Pubitemid 34548097)
60. Marshall OJ (2004). PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics 20 (15), 2471-2472.